On June 25, the 2026 PDI Pharmaceutical R&D & Innovation Conference and Launch Ceremony of Top 100 Pharmaceutical R&D Rankings (the 11th PDI Conference) grandly kicked off in Chengdu, Sichuan Province, where the 2026 China Pharmaceutical R&D Strength Ranking Series was officially released. Relying on its steadily growing comprehensive strength, Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was once again included in the Top 20 Chinese Pharmaceutical CDMO Enterprises list with an improved ranking.
This authoritative ranking is selected based on ten core indicators: annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, staff size, staff expansion rate, brand recognition and leading position in niche segments, representing the highest benchmark of China’s pharmaceutical CDMO sector. Being shortlisted for two consecutive years fully demonstrates that Tianshu Pharmaceutical has won high recognition and affirmation from industry authorities and peers in terms of overall competitiveness, technical expertise and industrial influence.
Expanding Production Capacity and Accelerating Industrial Layout
To cater to surging business demands, Tianshu Pharmaceutical is pressing ahead with capacity expansion projects. Workshop 3 and Workshop 4 are currently under planning and design. Upon completion, they will significantly boost the company’s large-scale manufacturing capacity for high-end APIs and key intermediates, further solidifying its one-stop CDMO service capacity spanning R&D through commercial production, and delivering more efficient and stable supply chain support to global clients.
Pursuing Green Development and Cultivating Core Technical Competencies
Driven by innovation, Tianshu Pharmaceutical has continuously built green manufacturing platforms and core technological strengths focusing on synthetic biology and continuous production technologies. The company actively develops and industrializes eco-friendly, safe, intelligent and advanced engineering technologies including continuous flow chemistry, micro-packed bed reactors, metal catalysis and biocatalytic enzyme technology. These technologies help cut production costs, shorten delivery lead times and lower environmental footprint, enabling the delivery of more efficient, high-quality and sustainable products and services to partners.
Optimizing One-Stop Solutions and Building a Global Collaboration Ecosystem
Upholding its corporate mission of "Empowering Global Clients with Differentiated Technologies", Tianshu Pharmaceutical centers on proprietary differentiated technologies, prioritizes advanced manufacturing and guarantees full compliance through robust quality systems. It provides global pharmaceutical companies and new drug R&D institutions with full-lifecycle one-stop CDMO solutions covering the R&D, production and supply of innovative drugs, high-end APIs and advanced pharmaceutical intermediates.
Tianshu Pharmaceutical will keep upgrading its drug R&D and manufacturing service platforms, actively build an open cooperation platform and win-win ecosystem for worldwide pharmaceutical enterprises, and continuously contribute Tianshu’s strength to the innovative growth of the pharmaceutical industry.
